If you have been reading about RP-HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-09. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
== Clinical trials == In clinical studies, Selank has been investigated for its potential effects on cognitive function and anxiety. It has also been compared with traditional anxiolytic drugs such as benzodiazepines and barbiturates. Selank is closely related to Semax, a nootropic also developed by same Institute of Molecular Genetics of the Russian Academy of Sciences. Both drugs are currently available in Russian and Ukrainian pharmacies. As with all lyophilized peptides, it needs refrigeration to remain stable within sterile water solutions, such as bacteriostatic water concentrations.
Silent strokes typically cause lesions which are detected via the use of neuroimaging such as fMRI. The risk of silent stroke increases with age but may also affect younger adults. Women appear to be at increased risk for silent stroke, with hypertension and current cigarette smoking being predisposing factors.
1993/2589) Mental Health Services of Salford National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2590) Hartlepool Community Care National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2591) Blackburn, Hyndburn and Ribble Valley Health Care National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2592) Northumberland Community Health National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2593) North Manchester Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2594) Community Healthcare Bolton National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2595) CommuniCare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2596) Blackpool, Wyre and Fylde Community Health Services National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2597) Blackpool Victoria Hospital National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2598) Bury Health Care National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2599)
Sources: en.wikipedia.org
In New Hampshire, many summits rise above 5,000 ft (1,500 m), including Mount Washington in the White Mountains at 6,288 ft (1,917 m), Adams at 5,771 ft (1,759 m), Jefferson at 5,712 ft (1,741 m), Monroe at 5,380 ft (1,640 m), Madison at 5,367 ft (1,636 m), Lafayette at 5,249 feet (1,600 m), and Lincoln at 5,089 ft (1,551 m). In the Green Mountains the highest point, Mt. Mansfield, is 4,393 ft (1,339 m) in elevation; others include Killington Peak at 4,226 ft (1,288 m), Camel's Hump at 4,083 ft (1,244 m), Mt. Abraham at 4,006 ft (1,221 m), and a number of other heights exceeding 3,000 ft (900 m).
== Career == Awadis and his older brother Brandon (known online as Brawadis) started a shared YouTube channel called "fathersonchaldean" and posted their first video on the same day, October 11, 2008. They uploaded at least three more videos by the end of 2009. Afterwards, the channel became inactive, but is still on YouTube. These videos depicted a stereotypical view of a Chaldean father's attitude towards his son. Awadis created his own YouTube channel on July 11, 2012 under the name FaZe Rug on which he started posting short clips of Call of Duty gameplay. He was invited to join the esports team FaZe Clan, which Awadis would eventually co-own, in January 2013. He uploaded his first prank video on December 7, 2014. He spent the next thirteen years as a member of FaZe Clan. While YouTube remained his primary focus, Awadis expanded into several other entertainment ventures. In November 2019, Awadis released a song called "Goin' Live". A few months later, he was the featured guest in season 17, episode 7 of MTV's Ridiculousness on June 24, 2020. Awadis co-founded 1UP Candy in 2023, a candy brand that specializes in freeze dried candy. On December 27, 2025, Awadis announced that he had left FaZe Clan through a post on X. Following his departure, he has continued to pursue independent content on the YouTube platform while retaining the name "FaZe Rug".
Lechleiter had served as Lilly's president and chief operating officer since October 2005. In October 1998, Lilly formed a 50-50 joint venture with Icos, a Bothell, Washington-based biotechnology company, to develop and commercialize Tadalafil (Cialis), for the treatment of erectile dysfunction. Lilly agreed to pay Icos an upfront fee of $75 million.
Sources: en.wikipedia.org
A number of different structural domains that fold mostly on their own have been found in the APP sequence. The extracellular region, much larger than the intracellular region, is divided into the E1 and E2 domains, linked by an acidic domain (AcD); E1 contains two subdomains including a growth factor-like domain (GFLD) and a copper-binding domain (CuBD) interacting tightly together. A serine protease inhibitor domain, absent from the isoform differentially expressed in the brain, is found between acidic region and E2 domain. The complete crystal structure of APP has not yet been solved; however, individual domains have been successfully crystallized, the growth factor-like domain, the copper-binding domain, the complete E1 domain and the E2 domain.
==== 1980s ==== The first Starbucks to sell brewed coffee opened in 1982. Later that year, the company hired Howard Schultz, who was behind the push to begin selling brewed coffee. The company opened its first espresso bar in 1984. That year, the original owners of Starbucks, led by Jerry Baldwin, purchased Peet's Coffee. By 1986, the company was operating six stores in Seattle and had begun to sell espresso coffee. Since the founders did not wish to expand too far from their original goal of that centered upon selling arabica coffee beans, Schultz left the company in 1985 to found Il Giornale, a cafe inspired the coffee bars he observed in Milan, Italy. Starbucks was the first investor in this venture, which used its beans in its beverages. In 1987, the original owners sold the Starbucks chain to Schultz, their former director of marketing, who rebranded his Il Giornale coffee outlets as Starbucks and began to expand the company. Also in 1987, Starbucks opened its first locations outside of Seattle, in Waterfront Station in Vancouver, British Columbia, and in Chicago, Illinois. By 1989, there were 46 Starbucks stores located across the Pacific Northwest and Midwest, and the company was roasting more than 2,000,000 pounds (907,185 kg) of coffee annually.
=== Dosage === When used to treat SVT, adenosine is administered intravenously as a rapid bolus (typically 0.10–0.15 mg/kg initially) over 1-2 seconds, followed by a rapid saline flush (often using a 2-way or 3-way stopcock). If the initial dose is ineffective, it may be repeated every 2 minutes with a slightly increased dose (0.05–0.1 mg/kg increments) every 2 minutes up to a maximum total dose of 0.3 mg/kg (not exceeding 12 mg). Due to adenosine's extremely short half-life (less than 10 seconds), it is often injected through a central venous line or a large proximal peripheral vein; administration into lower extremities, PICC lines, or smaller veins may lead to therapeutic failure due to rapid metabolism before reaching the heart. When given to dilate the arteries, such as in a "stress test", the dosage is typically 0.14 mg/kg/min, administered for 4 or 6 minutes, depending on the protocol. The recommended dose may be increased in patients on theophylline since methylxanthines prevent binding of adenosine at receptor sites. The dose is often decreased in patients on dipyridamole (Persantine) and diazepam (Valium) because adenosine potentiates the effects of these drugs. The recommended dose is also reduced by half in patients presenting congestive heart failure, myocardial infarction, shock, hypoxia, and/or chronic liver disease or chronic kidney disease, and in elderly patients.
Perching birds have a tendon-locking mechanism that helps them hold on to the perch when they are asleep. Many ground birds, such as quails and pheasants, roost in trees. A few parrots of the genus Loriculus roost hanging upside down. Some hummingbirds go into a nightly state of torpor accompanied with a reduction of their metabolic rates. This physiological adaptation shows in nearly a hundred other species, including owlet-nightjars, nightjars, and woodswallows. One species, the common poorwill, even enters a state of hibernation. Birds do not have sweat glands, but can lose water directly through the skin, and they may cool themselves by moving to shade, standing in water, panting, increasing their surface area, fluttering their throat or using special behaviours like urohidrosis to cool themselves.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.